There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Revolution Medicines (RVMD) and Spyre Therapeutics (SYRE) with bullish sentiments.
Revolution Medicines (RVMD)
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Revolution Medicines, with a price target of $315.00. The company’s shares closed last Friday at $207.88.
According to TipRanks.com, Zhu is a 5-star analyst with an average return of 28.8% and a 67.7% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Parabilis Medicines, Inc., Context Therapeutics, and Compass Therapeutics.
Revolution Medicines has an analyst consensus of Strong Buy, with a price target consensus of $245.70, which is a 10.9% upside from current levels. In a report issued on August 26, TipRanks – Google also upgraded the stock to Buy with a $237.00 price target.
